Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1911 1
1914 1
1930 1
1933 1
1937 1
1941 1
1946 2
1951 1
1952 1
1957 2
1958 1
1960 4
1961 3
1962 8
1963 2
1964 8
1965 3
1966 9
1967 11
1968 11
1969 14
1970 16
1971 30
1972 33
1973 29
1974 39
1975 147
1976 161
1977 148
1978 150
1979 175
1980 202
1981 226
1982 217
1983 256
1984 243
1985 313
1986 306
1987 335
1988 373
1989 421
1990 471
1991 483
1992 561
1993 547
1994 532
1995 549
1996 578
1997 570
1998 573
1999 566
2000 563
2001 595
2002 612
2003 654
2004 649
2005 728
2006 668
2007 710
2008 740
2009 759
2010 800
2011 853
2012 854
2013 946
2014 949
2015 916
2016 926
2017 946
2018 982
2019 998
2020 1363
2021 1564
2022 1365
2023 1131
2024 831

Text availability

Article attribute

Article type

Publication date

Search Results

29,291 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Antibody test negative"
Page 1
Diagnostic criteria for autoimmune encephalitis: utility and pitfalls for antibody-negative disease.
Dalmau J, Graus F. Dalmau J, et al. Lancet Neurol. 2023 Jun;22(6):529-540. doi: 10.1016/S1474-4422(23)00083-2. Lancet Neurol. 2023. PMID: 37210100 Review.
For diagnosis of possible autoimmune encephalitis and probable antibody-negative autoimmune encephalitis, clinicians should adhere to published criteria for adults and children, focusing particularly on exclusion of alternative disorders. Moreover, for diagnosis of …
For diagnosis of possible autoimmune encephalitis and probable antibody-negative autoimmune encephalitis, clinicians should ad …
Preclinical Efficacy of the Antibody-Drug Conjugate CLDN6-23-ADC for the Treatment of CLDN6-Positive Solid Tumors.
McDermott MSJ, O'Brien NA, Hoffstrom B, Gong K, Lu M, Zhang J, Luo T, Liang M, Jia W, Hong JJ, Chau K, Davenport S, Xie B, Press MF, Panayiotou R, Handly-Santana A, Brugge JS, Presta L, Glaspy J, Slamon DJ. McDermott MSJ, et al. Clin Cancer Res. 2023 Jun 1;29(11):2131-2143. doi: 10.1158/1078-0432.CCR-22-2981. Clin Cancer Res. 2023. PMID: 36884217 Free PMC article. Clinical Trial.
This expression profile makes CLDN6 an ideal target for development of a potential therapeutic antibody-drug conjugate (ADC). This study describes the generation and preclinical characterization of CLDN6-23-ADC, an ADC consisting of a humanized anti-CLDN6 monoclonal ant …
This expression profile makes CLDN6 an ideal target for development of a potential therapeutic antibody-drug conjugate (ADC). This st …
Anti-PD-1 antibodies recognizing the membrane-proximal region are PD-1 agonists that can down-regulate inflammatory diseases.
Suzuki K, Tajima M, Tokumaru Y, Oshiro Y, Nagata S, Kamada H, Kihara M, Nakano K, Honjo T, Ohta A. Suzuki K, et al. Sci Immunol. 2023 Jan 13;8(79):eadd4947. doi: 10.1126/sciimmunol.add4947. Epub 2023 Jan 13. Sci Immunol. 2023. PMID: 36638191
Here, we show that PD-1 agonists exist in the group of anti-PD-1 antibodies recognizing the membrane-proximal extracellular region in sharp contrast to the binding of the membrane-distal region by blocking antibodies. This trend was consistent in an analysis of 81 a …
Here, we show that PD-1 agonists exist in the group of anti-PD-1 antibodies recognizing the membrane-proximal extracellular region in …
Safety and immunogenicity of a single-shot live-attenuated chikungunya vaccine: a double-blind, multicentre, randomised, placebo-controlled, phase 3 trial.
Schneider M, Narciso-Abraham M, Hadl S, McMahon R, Toepfer S, Fuchs U, Hochreiter R, Bitzer A, Kosulin K, Larcher-Senn J, Mader R, Dubischar K, Zoihsl O, Jaramillo JC, Eder-Lingelbach S, Buerger V, Wressnigg N. Schneider M, et al. Lancet. 2023 Jun 24;401(10394):2138-2147. doi: 10.1016/S0140-6736(23)00641-4. Epub 2023 Jun 12. Lancet. 2023. PMID: 37321235 Free PMC article. Clinical Trial.
The primary endpoint was the proportion of baseline negative participants with a seroprotective chikungunya virus antibody level defined as 50% plaque reduction in a micro plaque reduction neutralisation test (muPRNT) with a muPRNT(50) titre of at least 150, …
The primary endpoint was the proportion of baseline negative participants with a seroprotective chikungunya virus antibody lev …
Nivolumab in melanoma.
Specenier P. Specenier P. Expert Rev Anticancer Ther. 2016 Dec;16(12):1247-1261. doi: 10.1080/14737140.2016.1249856. Epub 2016 Nov 7. Expert Rev Anticancer Ther. 2016. PMID: 27776441 Review.
The addition ipilimumab to nivolumab is associated with a higher response rate and a better PFS, particularly in patients with PD-L1 negative tumors, albeit at the cost of an increase in grade 3-4 adverse event rate. Definitive survival data on this combination are pending …
The addition ipilimumab to nivolumab is associated with a higher response rate and a better PFS, particularly in patients with PD-L1 nega …
Safety and immunogenicity of a live-attenuated influenza virus vector-based intranasal SARS-CoV-2 vaccine in adults: randomised, double-blind, placebo-controlled, phase 1 and 2 trials.
Zhu F, Zhuang C, Chu K, Zhang L, Zhao H, Huang S, Su Y, Lin H, Yang C, Jiang H, Zang X, Liu D, Pan H, Hu Y, Liu X, Chen Q, Song Q, Quan J, Huang Z, Zhong G, Chen J, Han J, Sun H, Cui L, Li J, Chen Y, Zhang T, Ye X, Li C, Wu T, Zhang J, Xia NS. Zhu F, et al. Lancet Respir Med. 2022 Aug;10(8):749-760. doi: 10.1016/S2213-2600(22)00131-X. Epub 2022 May 26. Lancet Respir Med. 2022. PMID: 35644168 Free PMC article. Clinical Trial.
METHODS: We did double-blind, randomised, placebo-controlled phase 1 and 2 trials, followed by a phase 2 extension trial, at a single centre in Jiangsu, China. Healthy adults (18 years) who had negative serum or fingertip blood total antibody tests for SARS-CoV-2 (i …
METHODS: We did double-blind, randomised, placebo-controlled phase 1 and 2 trials, followed by a phase 2 extension trial, at a single centre …
Evaluation of anti-SARS-CoV-2 antibody levels: two different methods.
Aslan Ö, Mızraklı A, Aktar GS, Onur AR. Aslan Ö, et al. Rev Assoc Med Bras (1992). 2021 Apr;67(4):597-601. doi: 10.1590/1806-9282.20201165. Rev Assoc Med Bras (1992). 2021. PMID: 34495067 Free article.
Patients underwent SARS-CoV-2 real-time polymerase chain reaction test, COVID-19 IgM/IgG antibody rapid test (Hotgen), and Roche SARS-CoV-2 antibody test. RESULTS: In this study, the positive values of COVID-19 IgM/IgG antibody rapid t …
Patients underwent SARS-CoV-2 real-time polymerase chain reaction test, COVID-19 IgM/IgG antibody rapid test (Hotgen), …
Randomized Phase II Study of the Safety and Efficacy of Semorinemab in Participants With Mild-to-Moderate Alzheimer Disease: Lauriet.
Monteiro C, Toth B, Brunstein F, Bobbala A, Datta S, Ceniceros R, Sanabria Bohorquez SM, Anania VG, Wildsmith KR, Schauer SP, Lee J, Dolton MJ, Ramakrishnan V, Abramzon D, Teng E; Lauriet investigators. Monteiro C, et al. Neurology. 2023 Oct 3;101(14):e1391-e1401. doi: 10.1212/WNL.0000000000207663. Epub 2023 Aug 29. Neurology. 2023. PMID: 37643887 Free PMC article. Clinical Trial.
Anti-tau immunotherapies were proposed as potential interventions in AD. While antibodies targeting N-terminal tau failed to demonstrate clinical efficacy in prodromal-to-mild AD, their utility at other disease stages was not evaluated in prior studies. ...DISCUSSION: Base …
Anti-tau immunotherapies were proposed as potential interventions in AD. While antibodies targeting N-terminal tau failed to demonstr …
Pathogenesis and mechanisms of antibody-mediated hemolysis.
Flegel WA. Flegel WA. Transfusion. 2015 Jul;55 Suppl 2(0):S47-58. doi: 10.1111/trf.13147. Transfusion. 2015. PMID: 26174897 Free PMC article. Review.
Several mechanisms of antibody-mediated hemolysis are well understood. Such hemolysis after transfusion is reliably avoided in a donor-recipient pair, if one individual is negative for the cognate antigen to which the other has the antibody. STUDY DESIGN …
Several mechanisms of antibody-mediated hemolysis are well understood. Such hemolysis after transfusion is reliably avoided in a dono …
Evaluation of rapid antibody test and chest computed tomography results of COVID-19 patients: A retrospective study.
Ozturk A, Bozok T, Simsek Bozok T. Ozturk A, et al. J Med Virol. 2021 Dec;93(12):6582-6587. doi: 10.1002/jmv.27209. Epub 2021 Aug 6. J Med Virol. 2021. PMID: 34260078 Free PMC article.
According to the SARS-CoV-2 RT-PCR results, the patients included in the study were divided into two groups: PCR positive group (n = 46) and PCR negative group (n = 274). The relationship between chest CT and rapid antibody test results were compared statisti …
According to the SARS-CoV-2 RT-PCR results, the patients included in the study were divided into two groups: PCR positive group (n = 46) and …
29,291 results
You have reached the last available page of results. Please see the User Guide for more information.